CVS Caremark expanded access for Eli Lilly’s obesity drugs by placing Foundayo on formularies starting June 1 and restoring Zepbound as a preferred option on Oct. 1, while keeping Novo Nordisk’s Wegovy preferred. Lilly said the changes align coverage across two major U.S. formularies previously contested in the GLP-1 market, with prescriptions expected to reach a broader pool of patients. Lilly’s Foundayo is an oral option, while Zepbound is injectable, and CVS coverage shifts could affect adoption curves and net pricing dynamics depending on employer-level plan design. The decision underscores that pharmacy benefit design remains a key determinant of obesity drug uptake alongside clinical performance and payer negotiations.